Nuvectra Corporation (NVTR) Shares Sold by SG Americas Securities LLC
SG Americas Securities LLC lessened its holdings in shares of Nuvectra Corporation (NASDAQ:NVTR) by 3.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 12,796 shares of the company’s stock after selling 422 shares during the period. SG Americas Securities LLC owned approximately 0.12% of Nuvectra Corporation worth $170,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Gilder Gagnon Howe & Co. LLC lifted its position in shares of Nuvectra Corporation by 12.5% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 953,431 shares of the company’s stock worth $12,662,000 after purchasing an additional 105,580 shares during the last quarter. Rockefeller Financial Services Inc. lifted its position in shares of Nuvectra Corporation by 3.2% during the 2nd quarter. Rockefeller Financial Services Inc. now owns 107,523 shares of the company’s stock worth $1,428,000 after purchasing an additional 3,338 shares during the last quarter. FNY Partners Fund LP lifted its position in shares of Nuvectra Corporation by 15.1% during the 1st quarter. FNY Partners Fund LP now owns 98,200 shares of the company’s stock worth $670,000 after purchasing an additional 12,900 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of Nuvectra Corporation by 0.7% during the 1st quarter. Wells Fargo & Company MN now owns 112,997 shares of the company’s stock worth $772,000 after purchasing an additional 751 shares during the last quarter. Finally, Hodges Capital Management Inc. lifted its position in shares of Nuvectra Corporation by 18.6% during the 2nd quarter. Hodges Capital Management Inc. now owns 227,807 shares of the company’s stock worth $3,025,000 after purchasing an additional 35,706 shares during the last quarter. 57.21% of the stock is owned by institutional investors and hedge funds.
Nuvectra Corporation (NASDAQ:NVTR) opened at 12.01 on Friday. Nuvectra Corporation has a 52 week low of $4.63 and a 52 week high of $12.19. The company’s market capitalization is $128.49 million. The company’s 50-day moving average price is $11.56 and its 200 day moving average price is $11.56.
Nuvectra Corporation (NASDAQ:NVTR) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($1.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.14) by $0.07. The firm had revenue of $7.20 million during the quarter, compared to the consensus estimate of $5.96 million. Nuvectra Corporation had a negative net margin of 232.31% and a negative return on equity of 56.68%. The business’s revenue for the quarter was up 188.0% compared to the same quarter last year. During the same period last year, the business posted ($0.85) earnings per share. On average, analysts predict that Nuvectra Corporation will post ($4.77) EPS for the current year.
In related news, CEO Scott F. Drees acquired 10,000 shares of the business’s stock in a transaction on Friday, August 11th. The stock was purchased at an average cost of $11.72 per share, for a total transaction of $117,200.00. Following the completion of the transaction, the chief executive officer now directly owns 125,180 shares of the company’s stock, valued at approximately $1,467,109.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 3.60% of the company’s stock.
NVTR has been the subject of several research analyst reports. TheStreet raised Nuvectra Corporation from a “d” rating to a “c-” rating in a research report on Monday, June 19th. ValuEngine raised Nuvectra Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 16th. Zacks Investment Research raised Nuvectra Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, May 30th. Finally, Piper Jaffray Companies reissued a “neutral” rating and set a $14.00 price objective on shares of Nuvectra Corporation in a research report on Thursday, July 6th. Three analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $10.50.
About Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
Want to see what other hedge funds are holding NVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvectra Corporation (NASDAQ:NVTR).
Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.